FUROSEMIDE TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

FUROSEMIDE

Disponible desde:

SANIS HEALTH INC

Código ATC:

C03CA01

Designación común internacional (DCI):

FUROSEMIDE

Dosis:

20MG

formulario farmacéutico:

TABLET

Composición:

FUROSEMIDE 20MG

Vía de administración:

ORAL

Unidades en paquete:

100/1000

tipo de receta:

Prescription

Área terapéutica:

LOOP DIURETICS

Resumen del producto:

Active ingredient group (AIG) number: 0101944002; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2015-02-18

Ficha técnica

1
PRODUCT MONOGRAPH
PR
FUROSEMIDE
FUROSEMIDE TABLETS
USP
20 MG, 40 MG AND 80 MG
DIURETIC
ATC Code: C03CA01
Sanis Health Inc.
1 President’s Choice Circle
Brampton, Ontario
L6Y 5S5
Submission Control No.: 250024
Date of Revision:
April 13, 2021
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
...................................................................................................
9
DRUG INTERACTIONS
.................................................................................................
12
DOSAGE AND ADMINISTRATION
.............................................................................
16
OVERDOSAGE
...............................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 18
STORAGE AND STABILITY
.........................................................................................
20
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 20
PART II: SCIENTIFIC INFORMATION
...............................................................................
21
PHARMACEUTICAL INFORMATION
.........................................................................
21
CLINICAL TRIALS
.........................................................................................................
21
DETAILED PHARMACOLOGY
....................................................................................
21
TOXICOLOGY
........